| # | Title | Journal | Year | Citations |
|---|
| 1 | STAT proteins: From normal control of cellular events to tumorigenesis | Journal of Cellular Physiology | 2003 | 522 |
| 2 | miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells | Journal of Cellular Physiology | 2010 | 190 |
| 3 | Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? | Cellular Immunology | 2019 | 187 |
| 4 | Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients | PLoS ONE | 2011 | 157 |
| 5 | Circular RNA in Exosomes | Advances in Experimental Medicine and Biology | 2018 | 139 |
| 6 | PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis | Oncotarget | 2016 | 134 |
| 7 | Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma | Cancer Treatment Reviews | 2010 | 128 |
| 8 | Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study | Annals of Oncology | 2018 | 124 |
| 9 | Liquid biopsies in lung cancer: The new ambrosia of researchers | Biochimica Et Biophysica Acta: Reviews on Cancer | 2014 | 123 |
| 10 | Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway | PPAR Research | 2017 | 119 |
| 11 | Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases | Journal of Cellular Physiology | 2011 | 118 |
| 12 | The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies | Expert Opinion on Therapeutic Targets | 2012 | 117 |
| 13 | Entrectinib: a potent new TRK, ROS1, and ALK inhibitor | Expert Opinion on Investigational Drugs | 2015 | 117 |
| 14 | Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? | Cancer Treatment Reviews | 2010 | 103 |
| 15 | Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway | Oncotarget | 2016 | 103 |
| 16 | Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study | Advances in Therapy | 2020 | 102 |
| 17 | Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy | Critical Reviews in Oncology/Hematology | 2019 | 100 |
| 18 | Breast cancer genome-wide association studies: there is strength in numbers | Oncogene | 2012 | 96 |
| 19 | Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer | Journal of Cellular Physiology | 2013 | 96 |
| 20 | Natural History of Non-Small-Cell Lung Cancer with Bone Metastases | Scientific Reports | 2015 | 95 |
| 21 | Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma | OncoImmunology | 2019 | 92 |
| 22 | Exosomes as diagnostic and predictive biomarkers in lung cancer | Journal of Thoracic Disease | 2017 | 90 |
| 23 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 | Breast Cancer Research | 2016 | 88 |
| 24 | Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis | Critical Reviews in Oncology/Hematology | 2016 | 81 |
| 25 | High density of tryptase‐positive mast cells in human colorectal cancer: a poor prognostic factor related to protease‐activated receptor 2 expression | Journal of Cellular and Molecular Medicine | 2013 | 80 |
| 26 | Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? | Analytical Cellular Pathology | 2015 | 80 |
| 27 | Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) | Advances in Therapy | 2019 | 80 |
| 28 | Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy | Breast Cancer Research and Treatment | 2012 | 73 |
| 29 | Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors | Cancer Treatment Reviews | 2014 | 70 |
| 30 | The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies | ESMO Open | 2021 | 69 |
| 31 | Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey | PLoS ONE | 2013 | 66 |
| 32 | The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis | Scientific Reports | 2018 | 66 |
| 33 | MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? | Oncotarget | 2015 | 65 |
| 34 | Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? | Journal of Experimental and Clinical Cancer Research | 2015 | 65 |
| 35 | Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer | Journal of Hematology and Oncology | 2017 | 65 |
| 36 | Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond | International Journal of Cardiology | 2017 | 64 |
| 37 | Insulin-Dependent Leptin Expression in Breast Cancer Cells | Cancer Research | 2008 | 62 |
| 38 | What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment | Oncotarget | 2015 | 57 |
| 39 | Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer | Advances in Experimental Medicine and Biology | 2016 | 55 |
| 40 | The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer | PPAR Research | 2017 | 55 |
| 41 | Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions | OncoImmunology | 2020 | 55 |
| 42 | A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience | Oncotarget | 2017 | 53 |
| 43 | Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives | Critical Reviews in Oncology/Hematology | 2019 | 51 |
| 44 | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer | Pharmaceuticals | 2020 | 51 |
| 45 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option | International Journal of Molecular Sciences | 2017 | 47 |
| 46 | KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting | Journal of Thoracic Disease | 2020 | 47 |
| 47 | Genetic and molecular characterization of the human Osteosarcoma 3AB‐OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness | Journal of Cellular Physiology | 2013 | 46 |
| 48 | MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? | Oncogenesis | 2012 | 45 |
| 49 | Co‐expression of CD133+/CD44+ in human colon cancer and liver metastasis | Journal of Cellular Physiology | 2013 | 45 |
| 50 | Cancer and the microbiome: potential applications as new tumor biomarker | Expert Review of Anticancer Therapy | 2015 | 45 |
